transcranial direct current stimulation and naming training for Alzheimer Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Baycrest Health Sciences, Toronto, Canada
Alzheimer Disease
transcranial direct current stimulation and naming training - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 3 months

3 months
Naming Training

Trial Safety

Trial Design

3 Treatment Groups

2mA Stimulation
1 of 3
4mA Stimulation
1 of 3
SHAM
1 of 3
Active Control
Experimental Treatment
Non-Treatment Group

42 Total Participants · 3 Treatment Groups

Primary Treatment: transcranial direct current stimulation and naming training · Has Placebo Group · N/A

4mA Stimulation
Device
Experimental Group · 1 Intervention: transcranial direct current stimulation and naming training · Intervention Types: Device
2mA Stimulation
Device
ActiveComparator Group · 1 Intervention: transcranial direct current stimulation and naming training · Intervention Types: Device
SHAM
Device
ShamComparator Group · 1 Intervention: transcranial direct current stimulation and naming training · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months
Closest Location: Baycrest Health Sciences · Toronto, Canada
Photo of Toronto 1Photo of Toronto 2Photo of Toronto 3
2019First Recorded Clinical Trial
9 TrialsResearching Alzheimer Disease
14 CompletedClinical Trials

Who is running the clinical trial?

Alzheimer's SocietyOTHER
8 Previous Clinical Trials
9,312 Total Patients Enrolled
2 Trials studying Alzheimer Disease
1,180 Patients Enrolled for Alzheimer Disease
BaycrestLead Sponsor
40 Previous Clinical Trials
5,663 Total Patients Enrolled
4 Trials studying Alzheimer Disease
411 Patients Enrolled for Alzheimer Disease

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.